Coronavirus, Covid-19 Vaccine Covaxin Latest Update: Bharat Biotech’s Covaxin

Bharat Biotech’s Covaxin is an inactivated vaccine against COVID-19 that has been developed in India. Here are some of the latest updates on Covaxin:

• Efficacy: In interim clinical trial data, Covaxin has been shown to have an efficacy rate of 77.8% against symptomatic COVID-19 cases. The vaccine has also been shown to be 93.4% effective against severe COVID-19 cases.
• Approval: Covaxin has been approved for emergency use by the World Health Organization (WHO), and has also been approved for use in India and several other countries.
• Booster dose: Bharat Biotech has reported that a booster dose of Covaxin has been shown to increase antibody levels significantly, and the company is planning to conduct a phase 3 clinical trial to evaluate the safety and efficacy of a third dose of the vaccine.
• Production capacity: Bharat Biotech has ramped up its production capacity for Covaxin, with the aim of producing 1 billion doses of the vaccine annually. The company has also signed agreements with several other countries to supply Covaxin.
• Variants: Bharat Biotech has reported that Covaxin is effective against the Delta variant of the virus, which is currently a major concern globally.

Overall, Covaxin has shown promising results in clinical trials and has been approved for emergency use in several countries.